Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Clinical Immunology

Managing Complex Immune Dysregulation

At a Glance

NFKB1-related immune dysregulation can cause weak infection defenses alongside harmful inflammation, autoimmunity, or immune-cell overgrowth. Treatment is individualized, with immunoglobulin replacement and close monitoring for infection, EBV, and enlarged nodes or spleen.

While infections are the most common challenge in NFKB1-related immune dysregulation, the condition often involves a second, more complex struggle: an immune system that doesn’t know when to stop. This leads to immune dysregulation, where your body may mistakenly attack its own tissues or allow certain cells to grow out of control [1].

The Paradox of Treatment

It may feel contradictory to be prescribed immunosuppressants—drugs that dampen the immune system—when you already have an immunodeficiency. However, when your immune system is dysregulated, it creates harmful inflammation while failing to effectively fight germs [2]. Doctors use these medications to quiet the “noise” (inflammation and autoimmunity) so your body can function more normally. To balance this, you will likely remain on immunoglobulin replacement therapy (IgRT), and require vigilant infection monitoring, because immunosuppression carries added infection risk [1].

Autoimmunity and Inflammation

Many people with an NFKB1 variant develop autoimmunity [1]. This most commonly affects the blood cells, leading to:

  • Autoimmune Cytopenias: The body attacks its own blood cells, resulting in low platelets (ITP) or low red blood cells (anemia) [3][4].
  • Gastrointestinal Symptoms: Chronic diarrhea and gut inflammation are commonly reported [1]. However, chronic diarrhea must first be evaluated for infections, medication effects, and celiac disease before being attributed to noninfectious enteropathy.
  • Autoinflammation: Some patients experience “unprovoked” inflammation, which can manifest as unexplained fevers or skin issues [1].

Treatments for these issues are highly individualized and may include corticosteroids (like prednisone) or targeted biologics such as rituximab [5][4]. It is important to note that rituximab broadly depletes CD20-positive B cells (not just those causing autoimmunity), which can worsen hypogammaglobulinemia and infection risk.

Lymphoproliferation and EBV Risks

Many NFKB1 patients experience lymphoproliferation, which is the overgrowth of immune cells [1]. This often causes an enlarged spleen (splenomegaly) or enlarged lymph nodes (lymphadenopathy) [6].

A specific concern in some patients is the Epstein-Barr Virus (EBV). While most people clear this common virus easily, people with NFKB1 may sometimes struggle to control it if T-cell function is severely impaired. If the virus stays active, it can occasionally trigger EBV-associated lymphoproliferative disease [7][4]. Your doctor may periodically check an EBV viral load (a blood test) if you have specific symptoms, lymphoproliferation, or are on immunosuppression. Note that detectable EBV DNA alone does not diagnose lymphoproliferative disease.

Hematopoietic Stem Cell Transplantation (HSCT)

For patients with severe, life-threatening complications that do not respond to medication, a Hematopoietic Stem Cell Transplant (HSCT)—sometimes called a bone marrow transplant—may be considered [1].

  • The Goal: To replace your immune system with a healthy one from a donor [8].
  • The Risks: This is an exceptional, high-risk procedure. Complications can include Graft-versus-Host Disease (GVHD), where the new immune system attacks your body, or severe infections during the recovery period [9][8].
  • Decision Making: Because it is so intensive, HSCT is currently reserved for carefully selected, severe, treatment-refractory cases [1].

When to Seek Evaluation vs Emergency Care

Most health issues with NFKB1—like a typical sinus infection or mild fatigue—can be handled with prompt outpatient care. However, it is vital to distinguish between a same-day evaluation and an emergency.

Call for prompt SAME-DAY clinical assessment if you experience:

  • A rapidly enlarging lymph node or persistent high fevers [4].
  • Drenching night sweats or unexplained weight loss.

Seek IMMEDIATE emergency medical care if you experience:

  • Breathing difficulty or shortness of breath.
  • Signs of shock or severe sepsis (e.g., severe dizziness, confusion, extreme lethargy).
  • Neurological Changes: Confusion, severe headaches, or sudden weakness, which can signal rare but serious central nervous system infections [10].
  • Severe Skin Changes: Redness, warmth, or pain in the skin that spreads very rapidly (over hours) or feels “out of proportion,” which could indicate severe soft-tissue inflammation or necrotizing fasciitis [11].

Common questions in this guide

Why can NFKB1-related disease cause both infections and autoimmunity?
NFKB1-related disease can weaken the immune response to germs while also causing harmful inflammation or immune cells to attack the body’s own tissues. This combination is why a person may need infection prevention and monitoring as well as treatment to calm the immune system.
Why would I take an immunosuppressant if I already have an immune deficiency?
Immunosuppressants are used to reduce harmful inflammation or autoimmunity, not to treat the underlying weakness against infections. Because these medicines can increase infection risk, your team may continue antibody replacement, also called immunoglobulin therapy, and watch closely for new infections.
What symptoms could signal lymphoproliferation or a related complication?
A rapidly enlarging lymph node, persistent high fever, drenching night sweats, or unexplained weight loss should prompt same-day clinical assessment. An enlarged spleen can also occur, and your care team may monitor your spleen and lymph nodes over time.
Does a positive EBV blood test mean I have EBV-associated lymphoproliferative disease?
No. Detectable EBV DNA or a measurable viral load alone does not diagnose lymphoproliferative disease; clinicians interpret the result alongside symptoms, examination findings, lymph-node or spleen changes, and treatment context.
When should I seek emergency care with NFKB1-related immune dysregulation?
Seek immediate emergency care for trouble breathing, signs of shock or severe sepsis such as confusion or extreme lethargy, sudden neurological changes, or skin redness, warmth, and pain that spreads quickly. Rapidly enlarging lymph nodes, persistent high fevers, drenching night sweats, or unexplained weight loss generally call for same-day assessment rather than waiting.
When might a hematopoietic stem cell transplant be considered?
HSCT may be considered for carefully selected people with severe, life-threatening complications that do not respond to medication. It is a high-risk treatment that can cause graft-versus-host disease and serious infections, so the decision is made with a specialist transplant team.
How are gastrointestinal symptoms evaluated in NFKB1-related disease?
Chronic diarrhea should first be evaluated for infections, medication effects, and celiac disease before being attributed to noninfectious intestinal inflammation. If those causes are excluded, your team may discuss treatments such as steroids or selected biologic medicines.

Get notified when new evidence is published on NFKB1-related immune dysregulation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.

    Lorenzini T, Fliegauf M, Klammer N, et al.

    The Journal of allergy and clinical immunology 2020; (146(4)):901-911 doi:10.1016/j.jaci.2019.11.051.

    PMID: 32278790
  2. 2

    Biochemically deleterious human NFKB1 variants underlie an autosomal dominant form of common variable immunodeficiency.

    Li J, Lei WT, Zhang P, et al.

    The Journal of experimental medicine 2021; (218(11)) doi:10.1084/jem.20210566.

    PMID: 34473196
  3. 3

    Standardized Human Phenotype Ontology annotation enables high-quality phenotypic data capture in a real-world common variable immunodeficiency cohort.

    Campos LC, Favreau É, Greene D, et al.

    The Journal of allergy and clinical immunology 2026; doi:10.1016/j.jaci.2026.08.027.

    PMID: 42767568
  4. 4

    The Presentation, Diagnosis, and Management of Autosomal Dominant Common Variable Immunodeficiency Type XII with NFKB1 Mutation and Autoimmune Neutropenia Treated with Allogenic Stem Cell Transplantation.

    Gold M, Kannan C, Schofield A, et al.

    Hematology reports 2025; (17(5)) doi:10.3390/hematolrep17050049.

    PMID: 41148944
  5. 5

    Immunosuppressive therapy with rituximab in common variable immunodeficiency.

    Pecoraro A, Crescenzi L, Galdiero MR, et al.

    Clinical and molecular allergy : CMA 2019; (17()):9 doi:10.1186/s12948-019-0113-3.

    PMID: 31080365
  6. 6

    Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans.

    Tuijnenburg P, Lango Allen H, Burns SO, et al.

    The Journal of allergy and clinical immunology 2018; (142(4)):1285-1296 doi:10.1016/j.jaci.2018.01.039.

    PMID: 29477724
  7. 7

    NF-κB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation.

    Boztug H, Hirschmugl T, Holter W, et al.

    Journal of clinical immunology 2016; (36(6)):533-40 doi:10.1007/s10875-016-0306-1.

    PMID: 27338827
  8. 8

    Haploidentical Stem Cell Transplantation After TCR-αβ+ and CD19+ Cells Depletion In Children With Congenital Non-Malignant Disease.

    Giardino S, Bagnasco F, Falco M, et al.

    Transplantation and cellular therapy 2022; (28(7)):394.e1-394.e9 doi:10.1016/j.jtct.2022.04.002.

    PMID: 35405368
  9. 9

    Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial.

    Parta M, Kelly C, Kwatemaa N, et al.

    Journal of clinical immunology 2017; (37(6)):548-558 doi:10.1007/s10875-017-0422-6.

    PMID: 28752258
  10. 10

    Common variable immunodeficiency due to a novel variant in NFKB1 with a neonatal presentation of parechovirus meningitis and sepsis-like illness.

    Szczawińska-Popłonyk A, Popłonyk N, Bernat-Sitarz K, et al.

    Allergologia et immunopathologia 2025; (53(3)):31-40 doi:10.15586/aei.v53i3.1307.

    PMID: 40342112
  11. 11

    Truncating NFKB1 variants cause combined NLRP3 inflammasome activation and type I interferon signaling and predispose to necrotizing fasciitis.

    Nurmi K, Silventoinen K, Keskitalo S, et al.

    Cell reports. Medicine 2024; (5(4)):101503 doi:10.1016/j.xcrm.2024.101503.

    PMID: 38593810

This page is for informational purposes only and does not constitute medical advice. It explains management of NFKB1-related immune dysregulation; your immunologist and care team should guide treatment, monitoring, and decisions about urgent care.